About Xpresys Lung
Xpresys Lung is a Healthcare company based in Boulder (United States) founded in 2013, and was acquired by Biodesix in July 2018. Proteomics-based liquid biopsy for lung cancer is provided. The company was acqui-hired. Its focus areas include Life Sciences, Clinical Genomics, Sequencing Based and Liquid Biopsy. Its competitors include Guardant Health, GRAIL and Delfi Diagnostics; 3 of its 3 listed competitors have raised funding.
Company details
Provider of proteomics-based liquid biopsy test for lung cancer. The companys focus is on leveraging systems biology approaches and proteomic technologies to develop a diagnostic assay derived from a set of circulating protein biomarkers associated with lung cancer. The companys Xpresys Lung uses mass spectrometry to measure levels of a set of circulating proteins in addition to, but independent of other clinical factors such as age, smoking history, nodule size, and COPD diagnosis to diagnose lung cancer.
- Headquarters Boulder, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website xpresyslung.com
- Acquired by Biodesix (Jul 2018)
Investors in Xpresys Lung
Xpresys Lung has secured backing from 1 investor. Prominent investors backing the company include Biodesix.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Cancer detection diagnostics assays are developed and offered. | 2005 | biodesix.com | Boulder, United States |
Investor details for Xpresys Lung
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Xpresys Lung
2 dated milestones of Xpresys Lung across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Xpresys Lung is founded.
- Exit Acquired by Biodesix.
Competitors of Xpresys Lung
Xpresys Lung has 3 listed competitors in our database, 3 of them funded. They include Guardant Health, GRAIL and Delfi Diagnostics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| grail.com | 2016 | Menlo Park, United States | $2B | 491 | Circulating tumor DNA is screened for early cancer detection. | |
| delfidiagnostics.com | 2019 | Baltimore, United States | $331.59M | Provider of DNA sequencing for cancer detection |
Detailed competitors of Xpresys Lung
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Xpresys Lung (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Xpresys Lung
Xpresys Lung was founded in 2013.
Xpresys Lung is headquartered in Boulder, United States. It is registered at Boulder, Colorado, United States.
Provider of proteomics-based liquid biopsy test for lung cancer. The companys focus is on leveraging systems biology approaches and proteomic technologies to develop a diagnostic assay derived from a set of circulating protein biomarkers associated with lung cancer. The companys Xpresys Lung uses mass spectrometry to measure levels of a set of circulating proteins in addition to, but independent of other clinical factors such as age, smoking history, nodule size, and COPD diagnosis to diagnose lung cancer.
Xpresys Lung's top competitors include Guardant Health, GRAIL and Delfi Diagnostics.
Xpresys Lung has 1 investor. Key investors include Biodesix.
Yes. Xpresys Lung was acquired by Biodesix in July 2018.